The clinical course is described of a 28-year-old woman who was severely ill following ingestion of a Do-Do tablet (which consists of ephedrine, caffeine and theophylline), 24 h after discontinuing pheneizine treatment. Signs and symptoms were delayed for 8 h after which she developed encephalopathy, neuromuscular irritability, hypotension, sinus tachycardia, rhabdomyolysis and hyperthermia. Her illness was complicated by pneumonia and adult respiratory distress syndrome (ARDS). The management of monoamine oxidase inhibitor (MAOI) toxicity, which can arise from interactions and overdoses, is discussed. It should be remembered that, despite the increase in use of alternative and safer antidepressants, MAOI interactions still occur and unless they are managed appropriately, are potentially fatal. Patients need to be wamed that restrictions apply for up to 2 weeks after stopping the medication, and doctors need to be aware that serious interactions can occur in this time period.
Monoamine oxidase inhibitor interactions are well recognized and occasionally life threatening. However, they are now so uncommon that many doctors will not have experienced a case. It is surprisingly difficult to find guidelines on how to treat the complications that may arise. We report a case of near fatal drug interaction with pheneizine and ephedrine and discuss the management options.
CASE REPORT
A 28-year-old trainee social worker was brought to the accident and emergency (A&E) department with sudden onset of flushing, collapse and agitation whilst at a parents evening. The only history given at that time was that she had recently taken a 'DoDo' tablet for a 'wheezy cough'.
Initial examination revealed her to be flushed and agitated, but coherent with a temperature of 370C. She had a pulse rate of 150 beats min-1 and a blood pressure of 90/60 mmHg. Chest examination revealed widespread wheeze.
It was thought that she was suffering from anaphylactic shock and was treated with 100mg of intravenous hydrocortisone and 500 mL of haemaccel. Her blood pressure then returned to normal but there was no effect on her other symptoms. The following history emerged only after close questioning of the patient and her relatives. She had been becoming increasingly 'chesty' over the last 2 days and had taken 1 'Do-Do' tablet (containing 30 mg of caffeine, 18.31 mg of ephedrine hydrochloride and 100 mg of theophylline) 8 The hypertensive interactions are well described and clinicians are aware of the need to inform patients of dietary restrictions and drug interactions. However, what may be poorly emphasized is the need for continued vigilance for at least two weeks after stopping monoamine oxidase inhibitors; and the potentially fatal consequence of an interaction with indirect amines. This patient had been well informed of the foods she should avoid and told not to take any other medication whilst on pheneizine. Unfortunately, it was not stressed that this instruction applied for at least 2 weeks after stopping the medication.
'Do-Do' tablets are 'over the counter' preparations advertised to the public as being a relief for 'bronchial coughs', wheezing and breathlessness; being aware of the interactions of theopylline, the phar-
MANAGEMENT OF MAOI TOXICITY
The features of MAOI toxicity that may be seen with drug interactions or overdosage are: hypertension or hypotension, tachycardia, arrhythmias, hypothermia, hyperthermia and malignant hyperpyrexia, agitation and hallucinations, hyper-reflexia, convulsions and spasticity, urinary retention, rhabdomyolysis, disseminated intravascular coagulation and acute tubular necrosis. Special care should be observed with any drug used in the management of monoamine oxidase inhibitor toxicity in view of the many known interactions which occur with this class of drugs.6
(1) Hypertension is best controlled with slow intravenous injection of 5mg of phentolamine, mild to moderate hypertension may be treated with sublingual nifedipine.
(2) Hypotension should initially be treated with intravenous fluids. If this fails to produce an adequate response in association with severe hypotension then cautious use of directly acting sympathomimetics such as noradrenaline is suggested.7 It should always be remembered that their effects will be enhanced and they should be used with intensive monitoring facilities.
(3) Hyperpyrexia may respond to paracetamol and external cooling. If the rectal temperature Dangerous monoamine oxidase inhibitor interactions exceeds 390c then the trachea should be intubated and the patient given a neuromuscular blocking agent, such as atracurium. If this fails to control the temperature then dantrolene can be used.
(4) Agitation should initially be treated with diazepam, this is a safe first time treatment. Chlorpromazine may be used which will have a beneficial effect on hyperpyrexia and hypertension but several authorities discourage its use, as it may be complicated by coma, hypotension and cardiac arrest.8 '9 In severe cases of neuromuscular irritability patients may require the use of muscle relaxants and intubation with assisted ventilation.
(5) Seizures should be treated with phenytoin. 
